LNTH
What one share of Lantheus Holdings holds
In Vitro and In Vivo Diagnostic Substances
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
Lantheus Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $23.51 |
|---|---|
| Profit | $4.16 |
| Capex (buildings and equipment) | $0.38 |
| Free cash flow | $5.86 |
| Cash and investments | $9.09 |
| Debt | $8.75 |
| Book value | $20.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $9.24 | $0.82 | $0.23 | $1.29 | — | −$2.77 |
| 2017 | $8.52 | $3.17 | $0.45 | $0.96 | — | $0.61 |
| 2018 | $8.69 | $1.03 | $0.51 | $1.04 | — | $1.81 |
| 2019 | $8.66 | $0.79 | $0.55 | $1.45 | — | $2.92 |
| 2020 | $6.27 | −$0.25 | $0.00 | $0.30 | — | $7.69 |
| 2021 | $6.30 | −$1.06 | $0.00 | $0.80 | — | $6.86 |
| 2022 | $13.23 | $0.40 | $3.68 | $0.31 | — | $6.49 |
| 2023 | $18.46 | $4.65 | $0.65 | $3.70 | — | $11.68 |
| 2024 | $21.41 | $4.36 | $0.72 | $6.88 | — | $15.89 |
| 2025 | $22.52 | $3.41 | $0.53 | $5.17 | — | $16.87 |